• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    11/15/23 4:31:03 PM ET
    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Business Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AUGX alert in real time by email

    Gainers

    • Bone Biologics (NASDAQ:BBLG) stock moved upwards by 56.0% to $0.81 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 2.3 million shares, which is 878.8 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $2.5 million. The company's, Q3 earnings came out yesterday.
    • Exagen (NASDAQ:XGN) stock rose 15.78% to $1.76. The market value of their outstanding shares is at $29.6 million. As per the press release, Q3 earnings came out 2 days ago.
    • PAVmed (NASDAQ:PAVM) shares increased by 11.31% to $0.25. The company's market cap stands at $27.4 million. As per the news, the Q3 earnings report came out yesterday.
    • GRI Bio (NASDAQ:GRI) shares rose 9.9% to $1.22. The market value of their outstanding shares is at $3.6 million.
    • Surrozen (NASDAQ:SRZN) shares rose 6.2% to $0.4. The company's market cap stands at $12.3 million.
    • Heart Test Laboratories (NASDAQ:HSCS) shares increased by 6.0% to $0.16. Trading volume for this security closed at 31.8 million, accounting for 1722.0% of its average full-day volume over the last 100 days. The company's market cap stands at $1.7 million.

    Losers

    • Augmedix (NASDAQ:AUGX) shares decreased by 20.8% to $4.3 during Wednesday's after-market session. Today's trading volume for this security ended up closing at 66.5K shares, which is 29.6 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $175.4 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares declined by 15.94% to $0.24. The market value of their outstanding shares is at $5.5 million.
    • OpGen (NASDAQ:OPGN) stock declined by 9.34% to $0.44. The company's market cap stands at $4.7 million. As per the press release, Q3 earnings came out yesterday.
    • Autolus Therapeutics (NASDAQ:AUTL) shares declined by 9.2% to $3.85. The market value of their outstanding shares is at $669.8 million.
    • Baudax Bio (NASDAQ:BXRX) stock decreased by 8.66% to $0.17. The market value of their outstanding shares is at $1.5 million.
    • Cocrystal Pharma (NASDAQ:COCP) shares fell 8.29% to $1.66. The company's market cap stands at $16.8 million. As per the news, the Q3 earnings report came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AUGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUGX
    $AUTL
    $BBLG
    $BXRX

    CompanyDatePrice TargetRatingAnalyst
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Autolus Therapeutics plc
    $AUTL
    2/17/2026$9.00Buy
    H.C. Wainwright
    Exagen Inc.
    $XGN
    9/11/2025$15.00Buy
    B. Riley Securities
    Exagen Inc.
    $XGN
    7/30/2025$12.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Exagen Inc.
    $XGN
    7/23/2025$12.00Buy
    Craig Hallum
    Surrozen Inc.
    $SRZN
    1/30/2025$32.00Buy
    H.C. Wainwright
    Surrozen Inc.
    $SRZN
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 31, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the year ended December 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "We are delighted to report that our norovirus human

    3/31/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagno

    3/30/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Autolus Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $9.00

    2/17/26 8:13:55 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Exagen with a new price target

    B. Riley Securities initiated coverage of Exagen with a rating of Buy and set a new price target of $15.00

    9/11/25 8:42:21 AM ET
    $XGN
    Medical Specialities
    Health Care

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Aklog Lishan

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 6:53:45 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Mcgrath Dennis M

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 4:51:51 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Glennon Michael J

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 4:50:30 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    SEC Filings

    View All

    HeartSciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - HeartSciences Inc. (0001468492) (Filer)

    4/3/26 5:15:10 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    Cocrystal Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cocrystal Pharma, Inc. (0001412486) (Filer)

    4/2/26 8:30:27 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Surrozen Inc.

    DEFA14A - Surrozen, Inc./DE (0001824893) (Filer)

    4/1/26 4:25:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frost Phillip Md Et Al bought $19,952 worth of shares (20,000 units at $1.00) (SEC Form 4)

    4 - Cocrystal Pharma, Inc. (0001412486) (Issuer)

    2/25/26 4:10:11 PM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Leadership Updates

    Live Leadership Updates

    View All

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

    Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) (the "Company" or "Cocrystal") announces the completion of a private placement of units priced at-the-market under Nasdaq rules with 743,024 shares of its common stock at a purchase price of $1.39 per unit for proceeds of $1.03 million and unregistered warrants to purchase up to 1,486,048 shares of common stock at an exercise price of $1.24 per share. The warrants are exercisable upon issuance and will expire in 27 months. The four Investors in th

    10/30/25 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Financials

    Live finance-specific insights

    View All

    Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines are available for norovirus infection, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 31, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the year ended December 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "We are delighted to report that our norovirus human

    3/31/26 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagno

    3/30/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

    AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluationAutolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in ​lupus nephritis and pediatric ALL enrolling; initial clinical data from BOBCAT Phase 1 trial in pro

    3/27/26 7:00:00 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AUGX
    $AUTL
    $BBLG
    $BXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    SC 13G/A - EXAGEN INC. (0001274737) (Subject)

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

    SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

    11/14/24 4:34:39 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care